Asthma Impairment and Risk Questionnaire (AIRQ)

The Asthma Impairment and Risk Questionnaire (AIRQ) is a brief tool that combines current symptoms and future exacerbation risk into a single composite asthma control score.

In the past 2 weeks, has coughing, wheezing, SOB, or chest tightness bothered you during the day on more than 4 days?
No0Yes+1
In the past 2 weeks, has coughing, wheezing, SOB, or chest tightness woke you up from sleep more than 1 time?
No0Yes+1
In the past 2 weeks, has coughing, wheezing, SOB, or chest tightness limited the activities you want to do every day?
No0Yes+1
In the past 2 weeks, has coughing, wheezing, SOB, or chest tightness caused you to use your rescue inhaler or nebulizer every day?
No0Yes+1
In the past 2 weeks did you have to limit your social activities (such as visiting with friends/relatives or playing with pets/children) because of your asthma?
No0Yes+1
In the past 2 weeks did coughing, wheezing, shortness of breath, or chest tightness limit your ability to exercise?
No0Yes+1
In the past 2 weeks did you feel that it was difficult to control your asthma?
No0Yes+1
In the past 12 months, has coughing, wheezing, shortness of breath, or chest tightness caused you to take steroid pills or shots, such as prednisone or methylprednisolone?
No0Yes+1
In the past 12 months, has coughing, wheezing, shortness of breath, or chest tightness caused you to go to the emergency room or have unplanned visits to a health care provider?
No0Yes+1
In the past 12 months, has coughing, wheezing, shortness of breath, or chest tightness caused you to stay in the hospital overnight?
No0Yes+1

Indications for Use

Used for adolescents and adults to classify current asthma control by combining symptom impairment with prior exacerbation risk. Validated to predict future exacerbations over 12 months and discriminate control levels with high accuracy (AUC≈0.85) 1 [Level II evidence]; Spanish validation showed sensitivity 89% and specificity 80% for detecting uncontrolled asthma 2 [Level II evidence]. Supports treatment adjustment and shared decision‑making.

Insights & Cautions

Identifies both current impairment and future exacerbation risk, offering stronger prediction of 12‑month exacerbations than symptom‑only tools 1 [Level II evidence].

  • Strengths: Validated, reliable, responsive; MID ≈2 points 2 [Level II evidence].
  • Cautions: Not a standalone diagnostic tool; may overestimate control if exacerbation history is incomplete; limited pediatric generalizability (separate Peds‑AIRQ exists).